The State Of ADC Manufacturing: Practices, Challenges, And The Road Ahead

Antibody–drug conjugates (ADCs) are rapidly redefining oncology, with more than 1,400 candidates in development and increasingly complex designs pushing the boundaries of what these therapies can achieve. As innovation accelerates, manufacturing has become a critical differentiator—shaping timelines, costs, and ultimately clinical success. Survey insights from across biopharma and CDMOs reveal a landscape balancing strong satisfaction with current setups against persistent hurdles such as scale-up, analytical readiness, and regulatory variability. Shifting production models, growing reliance on specialized partners, and pressure from rising costs highlight both the progress made and the challenges ahead. Encouragingly, advances in automation, AI-driven process optimization, and next-generation linker and payload technologies are expected to drive meaningful improvements.

For teams navigating ADC development, gain a practical look at where operational strategies can evolve to keep pace with the next wave of innovation.